Ramon F Barajas1, Nicholas A Butowski2, Joanna J Phillips3, Manish K Aghi4, Mitchel S Berger4, Susan M Chang2, Soonmee Cha5. 1. Department of Radiology, Neuroradiology Section, Oregon Health & Science University, L340, 3181 S.W. Sam Jackson Park Rd. Portland, OR 97239. 2. Department of Neurological Oncology, University of California, San Francisco, California. 3. Department of Pathology, University of California, Box 0628 Bldg 350 Parnassus Ave, Room 307, San Francisco, CA 94143. 4. Department of Neurological Surgery, University of California, San Francisco, California. 5. Department of Radiology and Biomedical Imaging, Neuroradiology Section, University of California, Box 0628 Bldg 350 Parnassus Ave, Room 307, San Francisco, CA 94143; Department of Neurological Surgery, University of California, San Francisco, California. Electronic address: Soonmee.Cha@uucsf.edu.
Abstract
RATIONALE AND OBJECTIVES: The treatment of glioma with bevacizumab results in decreased enhancement, making it challenging to diagnose tumor recurrence. Therefore, the primary aim of this retrospective study was to determine if the underlying biological processes occurring within regions of recurrent glioblastoma in patients undergoing bevacizumab therapy influence morphologic and diffusion-weighted magnetic resonance (MR) imaging characteristics. MATERIALS AND METHODS: In this Health Insurance Portability and Accountability Act-compliant and institutional review board-approved study, 26 patients treated with bevacizumab for high-grade glioma underwent lesion-wide apparent diffusion coefficient analysis before therapy and at the time of clinical/radiological progression, allowing for stratification by the presence or absence of reduced diffusion. Lesions with reduced diffusion were classified into "block" or "salt & pepper" phenotypes. Eight of the 26 patients underwent image-guided tissue sampling at the time of suspected disease recurrence allowing for direct biological correlation. Clinical, histologic, and MR imaging differences between diffusion groups were assessed using a two-sample Welch t test. RESULTS: All patients had histologic evidence of recurrent disease with or without a background of treatment effect. Sixty-two percent of the cohort had developed reduced diffusion at clinical progression following bevacizumab. Image-guided tissue sampling demonstrated that treatment effect was not observed within regions of reduced diffusion. Recurrent tumor intermixed with treatment effect was more likely to be observed within the "salt & pepper" phenotype when compared to "block" phenotype. CONCLUSIONS: Following bevacizumab therapy, recurrent glioblastoma can manifest as nonenhancing regions characterized by reduced diffusion. Histologically, these MR imaging characteristics correlate with aggressive biological features of disease recurrence.
RATIONALE AND OBJECTIVES: The treatment of glioma with bevacizumab results in decreased enhancement, making it challenging to diagnose tumor recurrence. Therefore, the primary aim of this retrospective study was to determine if the underlying biological processes occurring within regions of recurrent glioblastoma in patients undergoing bevacizumab therapy influence morphologic and diffusion-weighted magnetic resonance (MR) imaging characteristics. MATERIALS AND METHODS: In this Health Insurance Portability and Accountability Act-compliant and institutional review board-approved study, 26 patients treated with bevacizumab for high-grade glioma underwent lesion-wide apparent diffusion coefficient analysis before therapy and at the time of clinical/radiological progression, allowing for stratification by the presence or absence of reduced diffusion. Lesions with reduced diffusion were classified into "block" or "salt & pepper" phenotypes. Eight of the 26 patients underwent image-guided tissue sampling at the time of suspected disease recurrence allowing for direct biological correlation. Clinical, histologic, and MR imaging differences between diffusion groups were assessed using a two-sample Welch t test. RESULTS: All patients had histologic evidence of recurrent disease with or without a background of treatment effect. Sixty-two percent of the cohort had developed reduced diffusion at clinical progression following bevacizumab. Image-guided tissue sampling demonstrated that treatment effect was not observed within regions of reduced diffusion. Recurrent tumor intermixed with treatment effect was more likely to be observed within the "salt & pepper" phenotype when compared to "block" phenotype. CONCLUSIONS: Following bevacizumab therapy, recurrent glioblastoma can manifest as nonenhancing regions characterized by reduced diffusion. Histologically, these MR imaging characteristics correlate with aggressive biological features of disease recurrence.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin Journal: Radiology Date: 2009-07 Impact factor: 11.105
Authors: A Gupta; R J Young; A I Holodny; A B Lassman; S Karimi; S Sood; Z Zhang; Q Mo; P H Gutin Journal: AJNR Am J Neuroradiol Date: 2011-05-19 Impact factor: 3.825
Authors: Joost J C Verhoeff; Olaf van Tellingen; An Claes; Lukas J A Stalpers; Myra E van Linde; Dirk J Richel; William P J Leenders; Wouter R van Furth Journal: BMC Cancer Date: 2009-12-16 Impact factor: 4.430
Authors: Rajan Jain; Lisa M Scarpace; Shehanaz Ellika; Roy Torcuator; Lonni R Schultz; David Hearshen; Tom Mikkelsen Journal: J Neurooncol Date: 2009-10-27 Impact factor: 4.130
Authors: A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen Journal: Neurology Date: 2008-03-04 Impact factor: 9.910
Authors: Johannes Rieger; Oliver Bähr; Klaus Müller; Kea Franz; Joachim Steinbach; Elke Hattingen Journal: J Neurooncol Date: 2009-12-25 Impact factor: 4.130
Authors: Ramon F Barajas; Kenneth A Krohn; Jeanne M Link; Randall A Hawkins; Jennifer L Clarke; Miguel H Pampaloni; Soonmee Cha Journal: Biomedicines Date: 2016-10-31
Authors: Maya S Graham; Simone Krebs; Tejus Bale; Kwaku Domfe; Stephanie M Lobaugh; Zhigang Zhang; Mark P Dunphy; Thomas Kaley; Robert J Young Journal: Neurooncol Adv Date: 2020-04-15
Authors: Jan Brabec; Faris Durmo; Filip Szczepankiewicz; Patrik Brynolfsson; Björn Lampinen; Anna Rydelius; Linda Knutsson; Carl-Fredrik Westin; Pia C Sundgren; Markus Nilsson Journal: Front Neurosci Date: 2022-04-21 Impact factor: 5.152